5AM Ventures — Activity | F4

5AM Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

3 milestones· MAR 2026 – APR 2026Show all

Milestone

Portfolio company Reprotech merged with TMRW Life Sciences to create comprehensive technology-enabled fertility cryostorage platform managing 1M+ specimens.

Reprotech

Reprotech5AM Ventures

prnewswire.comAPR 2, 2026

APR 2, 2026

Milestone

Independent Data Monitoring Committee recommended initiation of Cohort 2 in Entrada's ELEVATE-44-201 gene therapy trial at increased dose.

Entrada Therapeutics

Entrada Therapeutics5AM Ventures

5amventures.comMAR 17, 2026

MAR 17, 2026

Milestone

Portal Instruments signed multi-million dollar development agreement to advance PRIME NEXUS large volume reusable autoinjector to clinical readiness.

Portal Instruments

Portal Instruments5AM Ventures

5amventures.comMAR 17, 2026

MAR 17, 2026

Exit

Portfolio company Wildcat Discovery Technologies acquired by Swedish battery technology firm Holyvolt for $73M.

Wildcat Discovery Technologies

Wildcat Discovery Technologies5AM Ventures

holyvolt.comMAR 5, 2026

MAR 5, 2026

Milestone

NodThera appointed Geoff McDonough, M.D. as Chief Executive Officer.

NodThera

NodThera 5AM Ventures

5amventures.comFEB 4, 2026

FEB 4, 2026

3 investments· JAN 2026Show all

Investment

Co-led Mendra's $82M Series A alongside OrbiMed and 8VC for rare disease therapeutics using AI.

Mendra

Mendra 5AM Ventures

fenwick.comJAN 21, 2026

finance.yahoo.com

JAN 21, 2026

Investment

Participated in Precede Biosciences' $83.5M Series B for next-generation precision diagnostics.

Precede Biosciences

Precede Biosciences 5AM Ventures

5amventures.comJAN 12, 2026

precede.bio

JAN 12, 2026

Investment

Participated in Kinaset Therapeutics' $103M Series B for inhaled therapeutics in respiratory diseases.

Kinaset Therapeutics

Kinaset Therapeutics 5AM Ventures

5amventures.comJAN 10, 2026

JAN 10, 2026

Milestone

CAMP4 Therapeutics entered a strategic collaboration with GSK to advance RNA-based therapeutic discoveries.

CAMP4 Therapeutics

CAMP4 Therapeutics 5AM Ventures

5amventures.comDEC 18, 2025

DEC 18, 2025

Investment

Co-led ProLynx's $70M Series A for ultra-long-acting obesity medicines.

ProLynx

ProLynx 5AM Ventures

globenewswire.comDEC 11, 2025

DEC 11, 2025

Investment

Participated in Lifordi's $112M financing (including strategic investment from Sanofi) for antibody-drug conjugates in autoimmune disease.

Lifordi

Lifordi 5AM Ventures

businesswire.comNOV 18, 2025

NOV 18, 2025

Exit

Portfolio company Cidara Therapeutics acquired by Merck for $9.2B for long-acting antiviral flu therapy.

Cidara Therapeutics

Cidara Therapeutics5AM Ventures

merck.comNOV 14, 2025

NOV 14, 2025

Exit

Portfolio company MapLight Therapeutics completed its IPO in October 2025.

MapLight Therapeutics

MapLight Therapeutics5AM Ventures

cbinsights.comOCT 27, 2025

ir.maplightrx.com

OCT 27, 2025

Investment

Led Fellow Health's $24M Series B to expand male reproductive health testing and diagnostics.

Fellow Health

Fellow Health5AM Ventures

businesswire.comJUL 15, 2025

businesswire.com

JUL 15, 2025

Page 1 of 2